|
Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst) |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Speakers' Bureau - Amgen; Janssen |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
William Jeffery Edenfield |
Speakers' Bureau - Astellas Medivation; Novartis |
|
|
Consulting or Advisory Role - Merck |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; G1 Therapeutics; Genentech/Roche; Janssen; Lilly; Regeneron |
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Lycera (Inst); Novartis (Inst); Regeneron (Inst); Transgene (Inst) |
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA. |
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Regeneron |